MedTrace Logo

What Laxative Should be Used After Hip Fracture Surgery?

NCT06455813 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 375

Last updated 2025-07-31

No results posted yet for this study

Summary

To conduct a randomized clinical trial to determine how best to prevent constipation after hip fracture surgery using laxatives.

Conditions

  • Hip Fractures

Interventions

DRUG

Bisacodyl

The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents

DRUG

Macrogol 3350 and electrolytes

The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents

DRUG

A combination of macrogol 3350 and electrolytes and bisacodyl

The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents

Sponsors & Collaborators

  • Independent Research Fund Denmark

    collaborator INDUSTRY

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Carina Lundby · Odense University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-07
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06455813 on ClinicalTrials.gov